Published :
Tables : 45
Figures : 41
Category : Healthcare
No. of Pages : 213
Report Code : HC-U3640
Alpha Thalassemia Market is estimated to register a CAGR of over 8.6% during the forecast period 2020 to 2027 FutureWise Market Research has instantiated a report that provides an intricate analysis of Alpha Thalassemia Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Alpha Thalassemia Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Alpha Thalassemia Market: • Pharmaceuticals Inc • Alnylam Pharmaceuticals Inc • Calimmune Inc • CRISPR Therapeutics • Editas Medicine Inc • Errant Gene Therapeutics LLC • Gamida Cell Ltd • Gilead Sciences Inc • Incyte Corp • Ionis Pharmaceuticals Inc • IRBM Science Park SpA • Johnson & Johnson • Kiadis Pharma NV • La Jolla Pharmaceutical Company • Merck & Co Inc • PharmaEssentia Corp • Protagonist Therapeutics Inc • Sangamo Therapeutics Inc • Zydus Cadila Healthcare Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends) Alpha Thalassemia Market Segmentation: By Type • Hb Bart syndrome • HbH disease • Silent Carrier State • Trait By Diagnosis • Perinatal Testing o Complete Blood Count (CBC) o DNA testing • Prenatal Testing o Prenatal Genetic Testing o Chorionic Villus Sampling • Pre-Implantation By Treatment • Blood Transfusions • Iron Chelation • Bone Marrow • Stem Cell Transplant • Surgery • Gene Therapy By End-User • Hospitals • Biotechnological laboratories • Diagnostic Laboratories • Educational Research Institutes • Pharmaceutical Industries • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Alpha Thalassemia Market By Type, By Diagnosis By Treatment, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has instantiated a report that provides an intricate analysis of Alpha Thalassemia Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Alpha Thalassemia Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Alpha Thalassemia Market: • Pharmaceuticals Inc • Alnylam Pharmaceuticals Inc • Calimmune Inc • CRISPR Therapeutics • Editas Medicine Inc • Errant Gene Therapeutics LLC • Gamida Cell Ltd • Gilead Sciences Inc • Incyte Corp • Ionis Pharmaceuticals Inc • IRBM Science Park SpA • Johnson & Johnson • Kiadis Pharma NV • La Jolla Pharmaceutical Company • Merck & Co Inc • PharmaEssentia Corp • Protagonist Therapeutics Inc • Sangamo Therapeutics Inc • Zydus Cadila Healthcare Ltd. (Note: The list of the major players will be updated with the latest market scenario and trends) Alpha Thalassemia Market Segmentation: By Type • Hb Bart syndrome • HbH disease • Silent Carrier State • Trait By Diagnosis • Perinatal Testing o Complete Blood Count (CBC) o DNA testing • Prenatal Testing o Prenatal Genetic Testing o Chorionic Villus Sampling • Pre-Implantation By Treatment • Blood Transfusions • Iron Chelation • Bone Marrow • Stem Cell Transplant • Surgery • Gene Therapy By End-User • Hospitals • Biotechnological laboratories • Diagnostic Laboratories • Educational Research Institutes • Pharmaceutical Industries • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Alpha Thalassemia Market By Type, By Diagnosis By Treatment, By End-User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Alpha Thalassemia Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Treatment Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Alpha Thalassemia Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Alpha Thalassemia Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Treatment Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Treatment Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Alpha Thalassemia Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Hb Bart syndrome 7.2. HbH disease 7.3. Silent Carrier State 7.4. Trait 8. Global Alpha Thalassemia Market, By Diagnosis Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Perinatal Testing 8.1.1. Blood Count (CBC) 8.1.2. DNA testing 8.2. Prenatal Testing 8.2.1. Prenatal Genetic Testing 8.2.2. Chorionic Villus Sampling 8.3. Pre-Implantation 9. Global Alpha Thalassemia Market, By Treatment Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Blood Transfusions 9.2. Iron Chelation 9.3. Bone Marrow 9.4. Stem Cell Transplant 9.5. Surgery and 9.6. Gene Therapy 10. Global Alpha Thalassemia Market, By End-User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Hospitals, 10.2. Biotechnological laboratories 10.3. Diagnostic Laboratories 10.4. Educational Research Institutes 10.5. Pharmaceutical Industries 10.6. Others 11. North America Alpha Thalassemia Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Alpha Thalassemia Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Alpha Thalassemia Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Alpha Thalassemia Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts) 17.1. Pharmaceuticals Inc 17.1.1. Company Overview 17.1.2. Type Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Alnylam Pharmaceuticals Inc 17.2.1. Company Overview 17.2.2. Type Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Calimmune Inc 17.3.1. Company Overview 17.3.2. Type Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. PathoFinder BV 17.4.1. Company Overview 17.4.2. Type Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5 Editas Medicine Inc 17.5.1. Company Overview 17.5.2. Type Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6 Errant Gene Therapeutics LLC 17.6.1. Company Overview 17.6.2. Type Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Gamida Cell Ltd 17.7.1. Company Overview 17.7.2. Type Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Gilead Sciences Inc 17.8.1. Company Overview 17.8.2. Type Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Incyte Corp 17.9.1. Company Overview 17.9.2. Type Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Ionis Pharmaceuticals Inc 17.10.1. Company Overview 17.10.2. Type Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.IRBM Science Park SpA 17.11.1. Company Overview 17.11.2. Type Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Johnson & Johnson 17.12.1. Company Overview 17.12.2. Type Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Kiadis Pharma NV 17.13.1. Company Overview 17.13.2. Type Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.La Jolla Pharmaceutical Company 17.14.1. Company Overview 17.14.2. Type Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Merck & Co Inc 17.15.1. Company Overview 17.15.2. Type Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 17.16.PharmaEssentia Corp 17.16.1. Company Overview 17.16.2. Type Portfolio 17.16.3. SWOT Analysis 17.16.4. Financial Overview 17.16.5. Strategic Overview 17.17.Protagonist Therapeutics Inc 17.17.1. Company Overview 17.17.2. Type Portfolio 17.17.3. SWOT Analysis 17.17.4. Financial Overview 17.17.5. Strategic Overview 17.18.Sangamo Therapeutics Inc 17.18.1. Company Overview 17.18.2. Type Portfolio 17.18.3. SWOT Analysis 17.18.4. Financial Overview 17.18.5. Strategic Overview 17.19.Zydus Cadila Healthcare Ltd. 17.19.1. Company Overview 17.19.2. Type Portfolio 17.19.3. SWOT Analysis 17.19.4. Financial Overview 17.19.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics